

Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Estimated one-year prevalence in patients with AD and individuals without AD, born in 1998, 1999, and 2000, treated with isotretinoin by age with 95% (CIs).

Age, y	<i>Patients with</i>		<i>Individuals</i>	
	<i>AD</i>	<i>without AD</i>		
	Number of Events	Proportion, 95%CIs	Number of Events	Proportion, 95%CIs
10	-	-	-	-
11	2	0.03(-0.01–0.08)	3	0.00 (0.00–0.01)
12	7	0.03 (0.01–0.05)	17	0.01 (0.01–0.02)
13	27	0.08 (0.05–0.11)	101	0.07 (0.05–0.08)
14	108	0.33 (0.27–0.40)	411	0.26 (0.24–0.29)
15	250	0.77 (0.68–0.87)	1,128	0.72 (0.67–0.76)
16	449	1.39 (1.26–1.52)	2,167	1.36 (1.31–1.42)
17	643	1.99 (1.83–2.14)	2,910	1.80 (1.74–1.87)
18	716	2.21 (2.05–2.37)	3,117	1.90 (1.84–1.97)
19	666	2.06 (1.90–2.21)	2,826	1.71 (1.64–1.77)
20	704	2.17 (2.01–2.34)	2,842	1.71 (1.65–1.77)
21	432	2.02 (1.83–2.21)	1,875	1.68 (1.61–1.76)
22	235	2.21 (1.92–2.49)	858	1.55 (1.44–1.65)

AD: Atopic Dermatitis; y: year; CIs: Confidence Intervals

Table SII. Estimated proportion of prescriptions dispensed for weak, moderate, and potent TCS per month with 95% CIs during isotretinoin treatment in patients with AD.

<i>TCS Potency</i>	<i>Month</i>	<i>Proportion</i>	<i>95% Cis</i>
Weak TCSs:	1	1.61	(0.67–3.89)
	2	2.73	(1.22–6.12)
	3	0.87	(0.32–2.39)
	4	2.48	(1.10–5.63)
	5	1.74	(0.73–4.13)
	6	1.24	(0.49–3.14)
	7	0.87	(0.32–2.39)
Moderate potent TCSs:	1	1.67	(0.94–2.96)
	2	2.36	(1.38–4.06)
	3	2.85	(1.68–4.83)
	4	2.58	(1.51–4.40)
	5	2.31	(1.34–3.98)
	6	1.34	(0.74–2.45)
	7	0.86	(0.44–1.68)
Potent TCSs:	0	2.68	(1.93–3.73)
	2	2.60	(1.87–3.62)
	3	2.60	(1.87–3.62)
	4	2.44	(1.75–3.40)
	5	1.54	(1.07–2.20)
	6	1.47	(1.03–2.12)
	7	1.43	(0.99–2.07)

AD: Atopic Dermatitis; Cis: Confidence Intervals; TCSs: Topical Corticosteroids